Hematological cancers are a uniquely diverse group of diseases that require expensive multi-disciplinary treatment teams and growing, often high-cost treatment options.
Over the last decade hematological cancers have increased approximately 30% and there is an increasing need to ensure that novel, expensive therapies reach the patients that will benefit the most from them.
Better targeted oncology care also reduces emergency cancer inpatient incidences and leads to improved cost effectiveness and patient outcomes.
Recently there have been remarkable progress in new medicines and therapies, but optimal use depends on new methods of molecular-level diagnostics.
Metadvice clinical decision engine enables this by providing more accurately tailored diagnostic and therapy decisions, by combining:
classical medical decision trees and blood analyses
patient-specific information e.g. demographics
disease-specific information e.g. genetic markers
similar patient case studies
In doing so, our solution enables more patient-specific oncology care and moves away from a ‘one size fits all’ approach.
This reduces emergency cancer inpatient incidences and leads to improved cost effectiveness and patient outcomes.
Metadvice can provide:
Realize opportunities for cost and time savings. Via optimum targeting of high cost tests and therapies for better planning and cost control.
Overview of common hematological malignancies:
Aligning classical medicine practices together with unique cases studies based on data Metadvice is refining diagnosis and treatment decisions for a more personalized approach in the following indications:
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Myelodysplastic Syndromes (MDS)